Ironwood Pharmaceuticals, Inc. - - IRWD STOCK NEWS

Ironwood Pharmaceuticals (NASDAQ: IRWD) announced that CEO Tom McCourt will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. ET. The presentation will be held virtually, and investors can access the live audio webcast via the company’s website. A replay will be available for 14 days post-conference. Ironwood is focused on advancing treatments for gastrointestinal diseases, including its flagship product LINZESS® for IBS-C and CIC.

Ironwood Pharmaceuticals announced the appointment of Sravan K. Emany as the new Chief Financial Officer effective December 6, 2021. Emany, who has extensive experience in financial strategy within the healthcare sector, will oversee all financial operations and report to CEO Thomas McCourt. McCourt expressed confidence that Emany's expertise will enhance Ironwood's impact on gastrointestinal (GI) healthcare and benefit shareholders. Previously, Emany held leadership roles at Integra LifeSciences and has 18 years in investment banking.

Ironwood Pharmaceuticals reported a strong third quarter in 2021, with GAAP net income of $55.8 million and adjusted EBITDA of $65.5 million. LINZESS prescription demand surged 12% year-over-year, driving U.S. net sales to $253 million, up 5% from the previous year. Ironwood ended the quarter with $574 million in cash. The company expanded its pipeline by entering into an option agreement with COUR Pharmaceuticals for CNP-104, targeting primary biliary cholangitis, a rare autoimmune disease. The firm anticipates 6% to 8% growth in LINZESS net sales for 2021.

Ironwood Pharmaceuticals (NASDAQ: IRWD) announced a collaboration with COUR Pharmaceutical for the investigational therapy CNP-104, aimed at treating Primary Biliary Cholangitis (PBC), a rare autoimmune disease affecting 133,000 people in the U.S. Ironwood will pay approximately $20 million upfront and could pay up to $475 million in milestones and royalties. The FDA has accepted the IND application for CNP-104, with clinical trials expected to commence soon, presenting significant potential for market expansion.

Ironwood Pharmaceuticals (NASDAQ: IRWD) will host its third quarter 2021 investor update conference call on November 4, 2021, at 8:30 a.m. ET. Interested participants can join via phone or webcast through the company's website. The call will be replayable starting November 4 at 11:30 a.m. ET until November 18, 2021. Ironwood is a leader in gastrointestinal healthcare, known for its innovation in treating GI diseases, specifically with its LINZESS® product for IBS-C and CIC. Founded in 1998, it is based in Boston, Massachusetts.

Ironwood Pharmaceuticals (NASDAQ: IRWD) will participate in two upcoming virtual investor conferences in September 2021. The Wells Fargo Healthcare Conference is scheduled for September 10 at 2:00 p.m. ET, and the Morgan Stanley 19th Annual Global Healthcare Conference will take place on September 13 at 2:45 p.m. ET. Investors can access live webcasts on Ironwood's website, with replays available for 14 days post-conference. Ironwood focuses on developing medicines for gastrointestinal diseases, notably linaclotide for IBS-C and CIC.

Ironwood Pharmaceuticals (NASDAQ: IRWD) announced FDA approval for a revised label of LINZESS (linaclotide) based on pediatric clinical safety data. The update narrows the boxed warning for dehydration risks to children under two years, previously applicable to all under 18. The labeling reflects ongoing studies to enhance safety profiles for pediatric use. LINZESS remains contraindicated for children under two, and its effectiveness for patients under 18 is not yet established. The drug is indicated for adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Ironwood Pharmaceuticals (Nasdaq: IRWD) reported robust Q2 2021 financial results, achieving total revenues of $104 million, a 16% increase from Q2 2020. GAAP net income surged to $391 million, or $2.42 per share, compared to $25 million, or $0.16 per share, in the prior year. LINZESS, its primary product, saw an 18% rise in U.S. net sales to $259 million. Ironwood raised its 2021 guidance, expecting total revenue of $390 to $410 million, driven by increasing demand for LINZESS. The company also highlighted promising developments in its pipeline, including IW-3300, targeting visceral pain conditions.